{"name":"BioVersys SAS","slug":"bioversys-sas","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Infectious Disease","slug":"infectious-disease","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"BV100 (300 mg)","genericName":"BV100 (300 mg)","slug":"bv100-300-mg","indication":"Serious bacterial infections caused by resistant gram-negative organisms (Phase 3 development)","status":"phase_3"},{"name":"MEROPENEM 2 grams TID","genericName":"MEROPENEM 2 grams TID","slug":"meropenem-2-grams-tid","indication":"Bacterial infections (specific indication under investigation by BioVersys SAS in Phase 3)","status":"phase_3"}]}],"pipeline":[{"name":"BV100 (300 mg)","genericName":"BV100 (300 mg)","slug":"bv100-300-mg","phase":"phase_3","mechanism":"BV100 is a benzoxaborole antibiotic that inhibits bacterial leucyl-tRNA synthetase, disrupting protein synthesis in susceptible pathogens.","indications":["Serious bacterial infections caused by resistant gram-negative organisms (Phase 3 development)"],"catalyst":""},{"name":"MEROPENEM 2 grams TID","genericName":"MEROPENEM 2 grams TID","slug":"meropenem-2-grams-tid","phase":"phase_3","mechanism":"Meropenem is a broad-spectrum beta-lactam antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins.","indications":["Bacterial infections (specific indication under investigation by BioVersys SAS in Phase 3)"],"catalyst":""}],"recentEvents":[],"realNews":[],"patents":[],"drugCount":2,"phaseCounts":{"phase_3":2},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}